Roles of CYLD and development of novel therapies for oral cancers
Project/Area Number |
22890146
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Surgical dentistry
|
Research Institution | Kumamoto University |
Principal Investigator |
SHINRIKI Satoru 熊本大学, 医学部附属病院, 特任助教 (00583048)
|
Project Period (FY) |
2010 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥2,977,000 (Direct Cost: ¥2,290,000、Indirect Cost: ¥687,000)
Fiscal Year 2011: ¥1,417,000 (Direct Cost: ¥1,090,000、Indirect Cost: ¥327,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 臨床腫瘍学 / CYLD / 口腔扁平上皮癌 / 浸潤 / 上皮間葉移行(EMT) / TGFBR1 / 低酸素 / 血管新生 |
Research Abstract |
We investigated expression of CYLD and its role in oral squamous cell carcinoma(OSCC). CYLD expression was significantly reduced at invasive lesions in OSCC tissues and correlated with poor prognosis. CYLD knockdown led to EMT-like changes in OSCC cell lines in the TGFBR1-dependent manner. Interestingly, CYLD repression led to resistance to cisplatin, but increased susceptibility to EGFR inhibitors-inducible apoptosis. Downregulation of CYLD may promote OSCC progression but EGFR may be an Achilles' heel of such aggressive cell populations. Further studies probably provide novel therapeutic strategies in OSCC.
|
Report
(3 results)
Research Products
(5 results)